ptcbio.com

Please wait for loading...




      (35):

    /
     5  +12 2014 sep 28ptc emailPTC Therapeutics: Contact UsIf you would like to subscribe to receive PTC updates, please enter your preferences below: ... Updates on PTC's Genetic Disorders Programs
     5  ~ 2014 sep 20video smaPTC Therapeutics: SMA ProgramSpinal Muscular Atrophy Program. PTC is committed to the development of treatments for rare and neglected disorders. Building on that ...
     6  +7 2014 sep 26therapeuticsPTC Therapeutics : HomeFocused on the discovery and commercialization of orally active small molecule therapeutics for human diseases.
     16  +8 2014 sep 29ptc wikiPTC Therapeutics: About UsPTC Therapeutics, Inc. ( PTC ) is a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small-molecule ...
     16  +34 2014 aug 17ptc site submissionPTC Therapeutics Reports Second Quarter ... - Investor RelationsThe Phase 3 study is expected to be conducted at 53 clinical sites ... In July 2013, PTC submitted responses to the Day 120 Questions to the ...
     19  +11 2014 aug 26ptc phone numberPTC Therapeutics: Location & DirectionsLocation Information PTC Therapeutics Inc. 100 Corporate Court South Plainfield , NJ 07080-2449. Phone :908-222-7000. Fax: 908-222-7231 info@ ptcbio .com.
     21  -10 2014 sep 30therapeutics inc
     23  +24 2014 sep 28ptc votePTC Therapeutics Receives Conditional Approval in the European PTC Therapeutics Receives Conditional Approval in the European Union for Translarna™ For the Treatment of Nonsense Mutation Duchenne ...
     23  +18 2014 sep 21pt cPTC Therapeutics: HomePTC applies its expertise in RNA biology and drug development to pioneer novel oral treatments for patients living with serious and life-threatening conditions.
     25  ~ 2014 sep 29path press of chicagoptc therapeutics recipient of parent project muscular dystrophy's... it is the recipient of Parent Project Muscular Dystrophy's (PPMD) " Path to ... The award was presented at PPMD's Annual Connect Conference in Chicago , ... FORWARD LOOKING STATEMENTS: This press release contains ...
     25  ~ 2014 aug 13font for treatment"We are delighted that Translarna was approved for the treatment of nonsense mutation Duchenne muscular dystrophy. By targeting the ...
     26  +75 2014 sep 10nonsense mutationPTC Therapeutics: AtalurenAtaluren (PTC124) is an investigational new drug by PTC Therapeutics in clinical trials in patients with nonsense mutation genetic disorders.
     27  +25 2014 sep 12ptc investigatorPTC Therapeutics: ACT DMD SitesUZ Leuven. Leuven Principal Investigator : Nathalie Goemans, MD Study Coordinator: Corine Antonis corine.antonis@uzleuven.be +32 16 34 0250 ...
     27  ~ 2014 aug 01inc email sunscriptionPTC Therapeutics, Inc . - Email Alert SubscriptionYou may automatically receive PTC Therapeutics, Inc . financial information by email . Please enter your preferences for email notifications below and click ...
     30  -8 2014 sep 20new ptc'sOurs Is a New Way of Looking. PTC applies its expertise in RNA biology and drug development to pioneer novel oral treatments for patients living with serious  ...
     31  +28 2014 sep 28what is ptc
     31  +29 2014 sep 15royal ptcThe Royal Children's Hospital. Parkville, VIC Principal Investigator: Monique Ryan, MD Study Coordinator: Daniella Villano daniella.villano@rch.org.au +61 (0 )3 ...
     32  +6 2014 aug 30ptc en venezuelaIf you would like to subscribe to receive PTC updates, please enter your preferences below: PTC Corporate Updates (All company financial, clinical or research ...
     33  -4 2014 aug 26becker muscular dystrophyAdvanced Duchenne/ Becker Muscular Dystrophy Genetic TestingGenetic Testing for Duchenne and Becker Muscular Dystrophy . Genetic tests find changes, called mutations, in genes that cause disease. These tests can be a ...
     33  -7 2014 aug 02update new ptcptc therapeutics provides update on chmp opinion for conditional PTC THERAPEUTICS PROVIDES UPDATE ON CHMP OPINION FOR ... If an appeal is unsuccessful, the Company could resubmit a new  ...
     34  -20 2014 sep 13does ptc sense workPTC Therapeutics: Culture and ValuesSENSE OF URGENCY — We do today what can be done today. ... We are committed to our work , strive to consistently meet deadlines and apply pride and  ...
     35  -23 2014 sep 19ptc indexptc therapeutics added to nasdaq biotechnology indexSOUTH PLAINFIELD, NJ – December 23, 2013 – PTC Therapeutics, Inc. ... The NASDAQ Biotechnology Index is designed to track the ...
     37  +27 2014 jul 28protein synthesis wordPTC Therapeutics: RNA BiologyThis protein synthesis machinery is capable of sequentially reading each three- letter genetic code " word " in mRNA and converting its respective encrypted ...
     43  ~ 2014 sep 12ptc sites newsPTC Therapeutics, Inc. - Press Releases - Investor RelationsPTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance. Year:.
     43  ~ 2014 aug 30best ptc programPTC Therapeutics Announces Expanded Access Program For -French ATU Cohort and Other Named Patient Programs Authorized - ... PTC's EAP program is intended to make Translarna™ (ataluren) available to patients before commercial availability in .... Close window | Back to top .
     53  ~ 2014 sep 27our company has been approved by well knownThe DMD community has been waiting a long time for treatment options and this conditional approval marks an important day for us all." ... For more information on the company , please visit our website www.ptcbio.com.
     60  -6 2014 sep 15protein synthesis and gene expressionThe normal course of gene expression involves the production of RNA by a ... To ensure that the appropriate proteins are always synthesized in the correct cells ...
     62  -30 2014 aug 15best ptc success planptc therapeutics appoints ronald c. renaud, jr. to ... - Investor RelationsHis demonstrated leadership experience in building successful biotechnology companies, his ... plans and prospects for PTC , the timing of regulatory approvals , the development of and potential ... Close window | Back to top .
     65  +27 2014 sep 09no minimum ptcPTC Therapeutics: ACT DMD OverviewPTC Therapeutics has initiated a Phase 3 clinical trial of ataluren (formerly ... for a minimum of 6 months immediately prior to the start of the study, with no  ...
     67  ~ 2014 aug 01facebook stock awards employeesptc therapeutics reports inducement grants under nasdaq listing rule Six of the stock option awards have an exercise price of $24.90 per ... of the applicable employee's new hire date and an additional 6.25% of ...
     68  +14 2014 jul 17ptc to get leadsPTC Therapeutics: Advanced Duchenne/Becker Muscular Dystrophy Genetic tests find changes, called mutations, in genes that cause disease. ... muscle cells become fragile and break down, and this leads to muscle weakness.
     69  -26 2014 jul 26single gene disordersPTC Therapeutics: Genetic DisordersCystic fibrosis is among the most common life-threatening genetic disorders worldwide. Cystic fibrosis is caused by defects in a single gene known as the cystic ...
     78  ~ 2014 jul 26murad director of marketingPTC Therapeutics: Murad HusainBoard of Directors ... In his role as Vice President of Regulatory Affairs, Mr. Murad Husain leads the regulatory efforts to support ... He received his M.S. in Pharmaceutical Marketing from St. John's University and his Masters and Bachelors in ...
     92  -29 2014 aug 13spinal muscular atrophyjoint program in spinal muscular atrophy enters ... - PTC TherapeuticsSMA is a genetic neuromuscular disorder that leads to muscle weakness and mobility impairment and is considered the leading genetic cause ...
     96  +5 2014 aug 18genetic background testingAdvanced Duchenne/Becker Muscular Dystrophy Genetic TestingGenetic Testing for Duchenne and Becker Muscular Dystrophy. Genetic tests find changes, called mutations, in genes that cause disease. ... Background
    1 of 1 pages